Zeria to pay $128 million for Tillotts Pharma
This article was originally published in Scrip
The mid-sized Japanese company Zeria has agreed to acquire 100% of the private Swiss firm Tillotts Pharma for SwFr136 million ($128 million). The transaction is expected to close next month and will strengthen Zeria's strategic focus on the gastrointestinal sector.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.